Monopar Therapeutics Inc. Profile Avatar - Palmy Investing

Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet…

Biotechnology
US, Wilmette [HQ]

Cash Flow Statements

Loading...
End of MNPR's Analysis
CIK: 1645469 CUSIP: 61023L108 ISIN: US61023L1089 LEI: - UEI: -
Secondary Listings
MNPR has no secondary listings inside our databases.